HealthQuill MASLD
US-based Akero Therapeutics, Inc., announced its mid-trial of a drug to treat fatty liver disease met its primary goals of efficacy and safety in patients, according to a company statement.
Drugs Health Pharma

Akero Therapeutics says mid-stage trials on drug for fatty liver disease positive

HQ Team March 4, 2024: US-based Akero Therapeutics, Inc., announced its mid-trial of a drug to treat fatty liver disease met its primary.

Read More
X